Business · 21/04/2025Updated: 10/17/2026 · 1 min read
FDA Approves AMVUTTRA (vutrisiran) Product Under Priority Review Voucher
Summary
The FDA has approved AMVUTTRA (vutrisiran), a product redeeming a priority review voucher, following a review of its supplemental application submitted by its sponsor.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →